IC
UTHR icon

Ikarian Capital’s United Therapeutics UTHR Stock Holding History

Ikarian Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,300
Closed -$964K – 224
2025
Q3 		$964K Buy
+2,300
New +$774K 0.1% 119
2022
Q2 		– Sell
-100,000
Closed -$17.9M – 203
2022
Q1 		$17.9M Buy
+100,000
New +$19.1M 2.36% 13
2021
Q2 		– Sell
-105,000
Closed -$17.6M – 288
2021
Q1 		$17.6M Buy
105,000
+35,700
+52% +$5.95M 0.59% 36
2020
Q4 		$10.5M Buy
+69,300
New +$9.09M 0.46% 50

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $49B AUM 17.78% 1-Year Est. Return

Ikarian Capital's UTHR Position: Q3 2022 in Review

Ikarian Capital sold out of United Therapeutics (UTHR) in Q3 2022, closing a stake of 40,000 shares — an estimated $9.43M sold.

Ikarian Capital first reported a position in UTHR in Q2 2022 and held it in 1 quarter. The position peaked at $9.43M in Q2 2022. 461 funds tracked by Wall St. Rank hold UTHR as of Q3 2022.

  • Ikarian Capital reported no remaining United Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Ikarian Capital sold 40,000 United Therapeutics shares in Q3 2022, an estimated $9.43M.
  • Ikarian Capital first reported a position in United Therapeutics in Q2 2022 and held it in 1 quarter.
  • Ikarian Capital's United Therapeutics position peaked at $9.43M in Q2 2022.
  • 461 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2022.

Based on Ikarian Capital's 13F filing for Q3 2022, filed 14 Nov 2022.